196 related articles for article (PubMed ID: 37211986)
1. Inhibition of SARS-CoV-2-mediated thromboinflammation by CLEC2.Fc.
Sung PS; Sun CP; Tao MH; Hsieh SL
EMBO Mol Med; 2023 Jul; 15(7):e16351. PubMed ID: 37211986
[TBL] [Abstract][Full Text] [Related]
2. CLEC5A and TLR2 are critical in SARS-CoV-2-induced NET formation and lung inflammation.
Sung PS; Yang SP; Peng YC; Sun CP; Tao MH; Hsieh SL
J Biomed Sci; 2022 Jul; 29(1):52. PubMed ID: 35820906
[TBL] [Abstract][Full Text] [Related]
3. What Role Does Microthrombosis Play in Long COVID?
Iba T; Connors JM; Levy JH
Semin Thromb Hemost; 2024 Jun; 50(4):527-536. PubMed ID: 37748518
[TBL] [Abstract][Full Text] [Related]
4. Thromboinflammation in long COVID-the elusive key to postinfection sequelae?
Nicolai L; Kaiser R; Stark K
J Thromb Haemost; 2023 Aug; 21(8):2020-2031. PubMed ID: 37178769
[TBL] [Abstract][Full Text] [Related]
5. C-type lectins and extracellular vesicles in virus-induced NETosis.
Sung PS; Hsieh SL
J Biomed Sci; 2021 Jun; 28(1):46. PubMed ID: 34116654
[TBL] [Abstract][Full Text] [Related]
6. Extracellular vesicles from CLEC2-activated platelets enhance dengue virus-induced lethality via CLEC5A/TLR2.
Sung PS; Huang TF; Hsieh SL
Nat Commun; 2019 Jun; 10(1):2402. PubMed ID: 31160588
[TBL] [Abstract][Full Text] [Related]
7. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
[TBL] [Abstract][Full Text] [Related]
8. Platelet-monocyte interaction amplifies thromboinflammation through tissue factor signaling in COVID-19.
Hottz ED; Martins-Gonçalves R; Palhinha L; Azevedo-Quintanilha IG; de Campos MM; Sacramento CQ; Temerozo JR; Soares VC; Dias SSG; Teixeira L; Castro Í; Righy C; Souza TML; Kurtz P; Andrade BB; Nakaya HI; Monteiro RQ; Bozza FA; Bozza PT
Blood Adv; 2022 Sep; 6(17):5085-5099. PubMed ID: 35420680
[TBL] [Abstract][Full Text] [Related]
9. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
Wang L; Yin J; Wang X; Shao M; Duan F; Wu W; Peng P; Jin J; Tang Y; Ruan Y; Sun Y; Gu J
Gastroenterology; 2016 May; 150(5):1183-1195.e16. PubMed ID: 26855187
[TBL] [Abstract][Full Text] [Related]
10. Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine.
Li CJ; Jiang CL; Chao TL; Lin SY; Tsai YM; Chao CS; Su YT; Chen CJ; Chang SY; Lin FJ; Chang SC
Appl Microbiol Biotechnol; 2023 May; 107(9):2983-2995. PubMed ID: 36988669
[TBL] [Abstract][Full Text] [Related]
11. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
[TBL] [Abstract][Full Text] [Related]
12. Kidney in the net of acute and long-haul coronavirus disease 2019: a potential role for lipid mediators in causing renal injury and fibrosis.
Chiang KC; Imig JD; Kalantar-Zadeh K; Gupta A
Curr Opin Nephrol Hypertens; 2022 Jan; 31(1):36-46. PubMed ID: 34846312
[TBL] [Abstract][Full Text] [Related]
13. A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity.
Yao X; Zhang Z; Mei Q; Li S; Xing L; Long Y; Zhang D; Wang J; Wang X; Xie B; Yang B; Gao Y; Wu C; Meng Q
Front Immunol; 2022; 13():1041860. PubMed ID: 36532082
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC).
Pretorius E; Venter C; Laubscher GJ; Kotze MJ; Oladejo SO; Watson LR; Rajaratnam K; Watson BW; Kell DB
Cardiovasc Diabetol; 2022 Aug; 21(1):148. PubMed ID: 35933347
[TBL] [Abstract][Full Text] [Related]
15. Thromboinflammation in coronavirus disease 2019: The clot thickens.
Iffah R; Gavins FNE
Br J Pharmacol; 2022 May; 179(10):2100-2107. PubMed ID: 34128218
[TBL] [Abstract][Full Text] [Related]
16. Myricetin possesses the potency against SARS-CoV-2 infection through blocking viral-entry facilitators and suppressing inflammation in rats and mice.
Pan H; He J; Yang Z; Yao X; Zhang H; Li R; Xiao Y; Zhao C; Jiang H; Liu Y; Li Z; Guo B; Zhang C; Li RZ; Liu L
Phytomedicine; 2023 Jul; 116():154858. PubMed ID: 37224774
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin yolk targeting spike 1, receptor binding domain of spike glycoprotein and nucleocapsid of SARS-CoV-2 blocking RBD-ACE2 binding interaction.
Eka Saputri M; Aisyah Rahmalia Effendi S; Nadila R; Azzam Fajar S; Damajanti Soejoedono R; Handharyani E; Nadia Poetri O
Int Immunopharmacol; 2022 Nov; 112():109280. PubMed ID: 36183680
[TBL] [Abstract][Full Text] [Related]
18.
Pandey AK; Verma S
Drug Dev Ind Pharm; 2022 Oct; 48(10):539-551. PubMed ID: 36250723
[TBL] [Abstract][Full Text] [Related]
19. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
[TBL] [Abstract][Full Text] [Related]
20. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
